Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM326 in Moderate to Severe COPD
NCT07418736Phase 2Recruiting
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Dec 2025
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of CM326 in chronic obstructive pulmonary disease (COPD), sponsored by CSPC ZhongQi Pharmaceutical Technology. Started Dec 2025; status: recruiting.
02
Drugs
CM326
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT07418736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07418736.